A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 571
- Registration Number
- NCT05456191
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Boulder, Colorado, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05454410
- Locations
- 🇺🇸
Interventional Psychiatry Tampa Bay, Tampa, Florida, United States
🇪🇸Novartis Investigative Site, Barcelona, Spain
🇺🇸Research Centers of America LLC ., Oakland Park, Florida, United States
Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 924
- Registration Number
- NCT05448872
- Locations
- 🇮🇹
Novartis Investigative Site, Trieste, Italy
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT05447663
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT05445843
- Locations
- 🇺🇸
The Brown University Oncology Group, Providence, Rhode Island, United States
🇬🇧Novartis Investigative Site, Torquay, United Kingdom
Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 489
- Registration Number
- NCT05440487
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT05432388
- Locations
- 🇺🇸
California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸Allergy and Asthma Clinical Research Inc, Walnut Creek, California, United States
🇺🇸University of Michigan Clinical Trials Office Drug Shipment (3), Ann Arbor, Michigan, United States
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸St Jude s Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05424523
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Special Drug Use-results Surveillance of Scemblix Tablets
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT05421091
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan